Trials / Completed
CompletedNCT03055741
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIb, Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Daehwa Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and safety of DHP1401 in patients with mild-moderate Alzheimer's disease treated with donepezil
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donepezil | 5mg or 10mg, once a day, 24 weeks |
| DRUG | DHP1401 | Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks |
| DRUG | Placebo | Placebo was administrated in two divided dosed a day for 24 weeks |
Timeline
- Start date
- 2016-12-28
- Primary completion
- 2019-02-01
- Completion
- 2019-08-01
- First posted
- 2017-02-16
- Last updated
- 2019-08-20
Locations
16 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03055741. Inclusion in this directory is not an endorsement.